Sarepta Therapeutics Target of Unusually Large Options Trading (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) was the recipient of some unusual options trading activity on Wednesday. Investors acquired 6,110 call options on the company. This is an increase of approximately 44% compared to the typical daily volume of 4,234 call options.

Insider Activity

In related news, Director Stephen Mayo sold 7,239 shares of the business’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $17.02, for a total transaction of $123,207.78. Following the transaction, the director owned 1,765 shares in the company, valued at $30,040.30. The trade was a 80.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 7.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. AQR Capital Management LLC increased its holdings in shares of Sarepta Therapeutics by 454.6% during the fourth quarter. AQR Capital Management LLC now owns 7,796,535 shares of the biotechnology company’s stock valued at $167,781,000 after acquiring an additional 6,390,860 shares in the last quarter. Vanguard Group Inc. boosted its stake in Sarepta Therapeutics by 18.1% in the 3rd quarter. Vanguard Group Inc. now owns 10,817,446 shares of the biotechnology company’s stock worth $208,452,000 after purchasing an additional 1,657,267 shares in the last quarter. First Trust Advisors LP boosted its stake in Sarepta Therapeutics by 209.1% in the 3rd quarter. First Trust Advisors LP now owns 1,939,781 shares of the biotechnology company’s stock worth $37,380,000 after purchasing an additional 1,312,220 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its position in Sarepta Therapeutics by 183.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,745,051 shares of the biotechnology company’s stock valued at $33,627,000 after purchasing an additional 1,129,610 shares during the last quarter. Finally, Erste Asset Management GmbH grew its position in Sarepta Therapeutics by 65.7% during the 3rd quarter. Erste Asset Management GmbH now owns 2,685,945 shares of the biotechnology company’s stock valued at $50,588,000 after purchasing an additional 1,064,530 shares during the last quarter. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Price Performance

Shares of SRPT opened at $23.77 on Thursday. Sarepta Therapeutics has a fifty-two week low of $10.41 and a fifty-two week high of $74.40. The firm’s 50-day simple moving average is $18.70 and its two-hundred day simple moving average is $19.96. The stock has a market cap of $2.50 billion, a PE ratio of -2.82, a price-to-earnings-growth ratio of 0.28 and a beta of 0.42. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.48 and a current ratio of 2.32.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($2.71). The business had revenue of $442.93 million for the quarter, compared to analysts’ expectations of $390.95 million. Sarepta Therapeutics had a negative net margin of 38.34% and a negative return on equity of 50.74%. Sarepta Therapeutics’s revenue for the quarter was down 32.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.90 earnings per share. Analysts anticipate that Sarepta Therapeutics will post 2.67 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Mizuho lifted their price objective on Sarepta Therapeutics from $26.00 to $31.00 and gave the company an “outperform” rating in a research report on Thursday, March 12th. Oppenheimer reissued an “outperform” rating and issued a $37.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, March 19th. HC Wainwright restated a “sell” rating on shares of Sarepta Therapeutics in a research note on Monday, March 2nd. Royal Bank Of Canada lifted their price target on Sarepta Therapeutics from $16.00 to $18.00 and gave the company a “sector perform” rating in a research report on Thursday, January 8th. Finally, Wedbush reduced their price target on Sarepta Therapeutics from $34.00 to $29.00 and set an “outperform” rating on the stock in a research note on Monday, March 2nd. Nine investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and six have issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $32.15.

Sarepta Therapeutics News Summary

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Early Phase 1/2 data showed dose-dependent muscle exposure, early biomarker effects and no dose-limiting toxicity for SRP-1001 and SRP-1003 — the company’s αvβ6 integrin delivery approach appears to get siRNA into muscle. Sarepta Announces First Clinical Data (BusinessWire)
• Positive Sentiment: Multiple outlets reported biomarker and protein reduction signals with favorable tolerability, reinforcing investor enthusiasm that these programs could address high-unmet-need neuromuscular disorders. Sarepta stock surges on early siRNA trial data (Investing.com)
• Positive Sentiment: Unusual options activity and heavy share volume point to speculative bullish positioning (notable call buying on the day), which amplifies upward price moves even absent confirmatory long-term data.
• Neutral Sentiment: Sarepta hosted a webcast/ conference call to present the data, providing more detail for investors and analysts to evaluate durability, effect size and safety across dose cohorts. Sarepta Announces First Clinical Data (Yahoo Finance)
• Negative Sentiment: Several analysts and commentators remain cautious — some call the results “promising but preliminary,” and note small sample sizes, short follow-up and unanswered questions about magnitude/durability of clinical benefit. Wall Street not wholly convinced (MSN)
• Negative Sentiment: Longer-term valuation and execution risks remain: Sarepta’s recent quarterly results showed a wide EPS miss and negative profitability metrics, underscoring that clinical progress must translate into durable revenue growth to justify lofty expectations. Valuation skepticism (Seeking Alpha)

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.